Commencement of the Phase 1 Clinical Trial of VectorFlu™ ONE

Phase 1 clinical trials of VectorFlu™ ONE, the world's first COVID-19 nasal vaccine, developed by the research team of HKU Department of Microbiology, commenced in March 2021 at the HKU Phase 1 Clinical Trials Centre.